Palos, I.; Lara-Ramirez, E.E.; Lopez-Cedillo, J.C.; Garcia-Perez, C.; Kashif, M.; Bocanegra-Garcia, V.; Nogueda-Torres, B.; Rivera, G.
Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies. Molecules 2017, 22, 1015.
https://doi.org/10.3390/molecules22061015
AMA Style
Palos I, Lara-Ramirez EE, Lopez-Cedillo JC, Garcia-Perez C, Kashif M, Bocanegra-Garcia V, Nogueda-Torres B, Rivera G.
Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies. Molecules. 2017; 22(6):1015.
https://doi.org/10.3390/molecules22061015
Chicago/Turabian Style
Palos, Isidro, Edgar E. Lara-Ramirez, Julio Cesar Lopez-Cedillo, Carlos Garcia-Perez, Muhammad Kashif, Virgilio Bocanegra-Garcia, Benjamin Nogueda-Torres, and Gildardo Rivera.
2017. "Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies" Molecules 22, no. 6: 1015.
https://doi.org/10.3390/molecules22061015
APA Style
Palos, I., Lara-Ramirez, E. E., Lopez-Cedillo, J. C., Garcia-Perez, C., Kashif, M., Bocanegra-Garcia, V., Nogueda-Torres, B., & Rivera, G.
(2017). Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies. Molecules, 22(6), 1015.
https://doi.org/10.3390/molecules22061015